--- title: "荃信生物：與羅氏達成 QX031N 的全球獨家許可協議，獲 7500 萬美元首付款" description: "荃信生物公告，公司與羅氏達成全球獨家合作與許可協議，根據協議，公司授予羅氏開發、生產及商業化 QX031N 的全球獨家權益。公司預計將獲得一次性、不可退還且不可抵扣的首付款 7500 萬美元，並有資格獲得與產品開發、監管批准及商業化相關的至多 9.95 億美元里程碑付款，以及潛在未來產品銷售的梯度特許權使用費。" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/263050947.md" published_at: "2025-10-28T09:52:31.000Z" --- # 荃信生物：與羅氏達成 QX031N 的全球獨家許可協議，獲 7500 萬美元首付款 > 荃信生物公告，公司與羅氏達成全球獨家合作與許可協議，根據協議，公司授予羅氏開發、生產及商業化 QX031N 的全球獨家權益。公司預計將獲得一次性、不可退還且不可抵扣的首付款 7500 萬美元，並有資格獲得與產品開發、監管批准及商業化相關的至多 9.95 億美元里程碑付款，以及潛在未來產品銷售的梯度特許權使用費。 荃信生物公告，公司與羅氏達成全球獨家合作與許可協議，根據協議，公司授予羅氏開發、生產及商業化 QX031N 的全球獨家權益。公司預計將獲得一次性、不可退還且不可抵扣的首付款 7500 萬美元，並有資格獲得與產品開發、監管批准及商業化相關的至多 9.95 億美元里程碑付款，以及潛在未來產品銷售的梯度特許權使用費。 ### Related Stocks - [02509.HK - 荃信生物-B](https://longbridge.com/zh-HK/quote/02509.HK.md) - [RHHBY.US - 羅氏(ADR)](https://longbridge.com/zh-HK/quote/RHHBY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued | Qyuns Therapeutics Co., Ltd. has initiated a share buyback program after the board determined that the stock is underval | [Link](https://longbridge.com/zh-HK/news/274983583.md) | | Rovi jumps after announcing drug deal with Roche | Shares in Rovi rose about 8% following the announcement of a drug manufacturing deal with Roche. The agreement is expect | [Link](https://longbridge.com/zh-HK/news/262092937.md) | | Obesity challenger Roche 'only scratching surface' of market potential, says CEO | Roche's CEO, Thomas Schinecker, expressed confidence in the growth potential of the weight-loss drug market, stating the | [Link](https://longbridge.com/zh-HK/news/262356985.md) | | Roche shares rise as company advances experimental obesity drug to late-stage trial | Roche Holding's shares rose approximately 2% as the company advanced its experimental obesity drug CT-388 to late-stage | [Link](https://longbridge.com/zh-HK/news/258317465.md) | | Roche raises guidance on forecast-beating nine-month sales | FRANKFURT, Oct 23 (Reuters) - Swiss drugmaker Roche (ROG.S) on Thursday lifted its full-year guidance after reporting ni | [Link](https://longbridge.com/zh-HK/news/262348155.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。